The Journal of Current Hematology & Oncology Research regularly publishes internationally qualified research in hematology and oncology within the current scholarly knowledge. This journal is indexed by indices that are considered international scientific journal indices (DRJI, ESJI, OAJI, etc.). According to the current Associate Professorship criteria, it is within the scope of International Article 1-d. Each article published in this journal corresponds to 5 points.

EndNote Style
Original Article
Does early granulocyte colony-stimulating factor administration in autologous peripheral blood stem cell transplantation shorten the duration of hospitalization in patients with multiple myeloma?
Aims: Autologous peripheral blood stem cell transplantation (PBSCT), performed with high-dose melphalan support following induction therapy is still the gold standard method of treatment for multipl myeloma (MM)patients suitable for transplantation. It was aimed, with this retrospective study, to investigate the effects of early (1 day after PBSCT) and late (5 days after PBSCT) initiation of granulocyte colony-stimulating factor (G-CSF) support following PBSCT on engraftment time, febrile neutropenia, and length of hospital stay (LOS) in MM patients.
Methods: This study included 70 patients with MM, who underwent PBSCT in Erciyes University. Two groups were administered 5µg/kg filgrastim, subcutaneously, either 1 day or 5 days after PBSCT, until neutrophil engraftment was reached.
Results: Both neutrophil and platelet engraftment occurred in significantly shorter times in the early G-CSF group compared to late G-CSF group; the median times to neutrophil engraftment were 10 (8-13) and 11 (7-15) days, respectively, and the median times to platelet engraftment were 11 (10- 16) and 13 (11- 21) days (p=0.001). Also, the median LOS was also significantly shorter in the early G-CSF group compared to late G-CSF group; 14 (10-22) vs 16 (11- 33) days, respectively (p=0.016). No significant difference was found between the groups in terms of frequency of febrile neutropenia.
Conclusion: The initiation of G-CSF support early, following PBSCT in MM patients, accelerated neutrophil and platelet engraftment and shortened the LOS as compared to the initiation of G-CSF support late, with no significant difference in the frequency of febrile neutropenia.

1. Attal M, Harousseau JL, Stoppa AM, et al. A prospective,randomized trial of autologous bone marrow transplantationand chemotherapy in multiple myeloma. N Engl J Med.1996;335(2):91-97. doi: 10.1056/nejm199607113350204
2. Trivedi M, Martinez S, Corringham S, Medley K, Ball ED.Optimal use of G-CSF administration after hematopoietic SCT.Bone Marrow Transplant. 2009;43(12):895-908.
3. Klumpp TR, Mangan KF, Goldberg SL, Pearlman ES,Macdonald JS. Granulocyte colony-stimulating factoraccelerates neutrophil engraftment following peripheral-bloodstem-cell transplantation: a prospective, randomized trial. JClin Oncol. 1995;13(6):1323-1327.
4. Schmitz N, Ljungman P, Cordonnier C, et al. Lenograstim afterautologous peripheral blood progenitor cell transplantation:results of a double-blind, randomized trial. 2004;34(11):955-962.
5. Smith TJ, Bohlke K, Lyman GH, et al. Recommendations forthe use of WBC growth factors: American Society of ClinicalOncology clinical practice guideline update. J Clin Oncol.2015;33(28):3199-3212.
6. Becker PS, Griffiths EA, Alwan LM, et al. NCCN guidelinesinsights: hematopoietic growth factors, version 1.2020: featuredupdates to the NCCN guidelines. J National Comprehens CancNetw. 2020;18(1):12-22.
7. Thompson JM, Carlton P, Akard LP, Dugan MJ, Jansen J.Starting granulocyte-colony-stimulating factor (filgrastim)early after autologous peripheral blood progenitor celltransplantation leads to faster engraftment without increasedresource utilization. Transfusion 2009;49(3):548-554. doi:10.1111/j.1537-2995.2008.02006.x
8. Sborov DW, Cho YK, Cottini F, et al. G-CSF improvessafety when you start the day after autologous transplant inmultiple myeloma. Leukem Lymph. 2017;58(12):2947-2951. doi:10.1080/10428194.2017.1318436
9. Singh AD, Parmar S, Patel K, et al. Granulocyte colony-stimulating factor use after autologous peripheral blood stemcell transplantation: comparison of two practices. Biol BloodMarrow Transplant. 2018;24(2):288-293.
10. Hillengass J, Usmani S, Rajkumar SV, et al. Internationalmyeloma working group consensus recommendationson imaging in monoclonal plasma cell disorders.Lancet Oncol. 2019;20(6):e302-e312. doi: 10.1016/S1470-2045(19)30309-2
11. Tekgündüz E, Altuntaş F, Şıvgın S, et al. Plerixafor use inpatients with previous mobilization failure: a multicenterexperience. Transfus Apheres Sci. 2012;47(1):77-80. doi:10.1016/j.transci.2012.05.004
12. Valteau-Couanet D, Faucher C, Auperin A, et al.Cost effectiveness of day 5 G-CSF (Lenograstim®)administration after PBSC transplantation: results of aSFGM-TC randomised trial. Bone Marrow Transplant.2005;36(6):547-552.
13. Singh AD, Parmar S, Patel K, et al. Granulocyte colony-stimulating factor use after autologous peripheral blood stemcell transplantation: comparison of two practices. Biol BloodMarrow Transplant. 2018;24(2):288-293.
14. Jackson ER, Jared JR, Piccolo JK, et al. Granulocyte colony-stimulating factor utilization postautologous hematopoieticstem cell transplant in multiple myeloma patients: does one sizefit all? J Oncol Pharm Pract. 2019;2(5):1135-1141.
15. Cox J, Campos S, Wu J, et al. Efficacy of deferred dosingof granulocyte colony-stimulating factor in autologoushematopoietic transplantation for multiple myeloma. BoneMarrow Transplant. 2014;49(2):219-222.
16. Gonçalves TL, Benvegnú DM, Bonfanti G. Specificfactors influence the success of autologous and allogeneichematopoietic stem cell transplantation. Oxidat Med CellulLongev. 2009;2(2):82-87. doi: 10.4161/oxim.2.2.8355
17. Turk HM, Komurcu S, Arpaci F, et al. Factors affectingengraftment time in autologous peripheral stem celltransplantation. Asian Pacif J Cancer Prevent. 2010;11(3):697-702.
Volume 2, Issue 2, 2024
Page : 41-46